Ultragenyx drug fails late-stage trial main goal
Ultragenyx Pharmaceutical said its experimental drug for a rare genetic neurodevelopmental disorder did not meet the main goal in a late-stage trial.
Ultragenyx Pharmaceutical NASDAQ:RARE said on Wednesday its experimental drug for a rare genetic neurodevelopmental disorder did not meet the main goal in a late-stage trial.